![Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era]()
Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI EraBellmunt, Joaquim; Esteban, Emilio; Muro, Xavier García del; Sepúlveda, Juan Manuel; Maroto, Pablo; Gallardo, Enrique; Alba, Aranzazu González del; Etxaniz, Olatz; Guix, Marta; Larriba, Jose Luis González; Arranz, Jose A.; Redrado, Miriam; Calvo, Alfonso · European Urology Oncology · 2019